Her2/neu immunostaining of formalin-fixed tumour tissues. Formalin-fixed, paraffin-embedded tissue blocks from the USC patients from whom primary cell lines were established were retrieved from ...

HER2/Neu is amplified and overexpressed in a large proportion of human breast cancers, but the signaling pathways that contribute to tumor development and metastatic progression are not completely ...

HER2-positive tumors can also be estrogen-receptor-positive (triple-positive breast cancer). However, ... The mutation causes the gene to produce too many HER2/neu proteins (or just HER2 proteins).

PATIENTS AND METHODS: Sixty-four patients with HER-2/neu–overexpressing breast, ovarian, or non–small-cell lung cancers were enrolled. Vaccines were composed of peptides derived from potential ...

Again, the roughly 15% of cases that overexpress HER2/neu are referred to as HER2/neu-amplified or HER2/neu-positive; this is very relevant for the physician team taking care of the patient with ...

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the pros and cons of biomarker-based ...

In late 2019, trastuzumab deruxtecan was approved for the treatment of metastatic HER2/neu-positive breast cancer based on a phase two single arm trial that showed an extremely high response rate ...

ITI Reports Preclinical Data on Its MCPγV-LT and Her2/Neu DNA Vaccines at the American Association for Cancer Research (AACR) Annual Meeting 2022 ...

Find out all you need to know about Herceptin (trastuzumab) for early and more advanced HER2-positive breast cancer, including what to expect, outcomes, side effects, and more.

In the Destiny-Breast04 trial, investigators used an investigational IHC test developed by Roche, the Ventana HER2/neu (4B5) IUO Assay system.

Proper treatment will be determined, in part, by the kind of cancer you have. Breast cancer can be classified as invasive or noninvasive. Types of breast cancer include invasive ductal carcinoma (IDC) ...